Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
UNCY · NASDAQ · Pharmaceutical Preparations
Unicycive Therapeutics (UNCY) · oqro.io/stocks/UNCY · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Unicycive Therapeutics was filed in the last 90 days. The latest on record was on May 16, 2022.
Since 2022, Unicycive Therapeutics insiders reported 1 open-market purchase and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2022.
No open-market sale by an insider of Unicycive Therapeutics (UNCY) was filed with the SEC in the last 90 days.
No trade in Unicycive Therapeutics (UNCY) was disclosed by a member of Congress in the last 12 months.
Unicycive Therapeutics's next results are expected on Nov 18, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$3.35−0.18 (−5.10%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−36.4% (−$1.92) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $5.27 on Nov 20, 2025 to $3.35 on Nov 20, 2026 (−36.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Mountain View, Ca.
Last 12 months
−36.4%
Market value
$103M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 4.82M shares sold short (15.7% of shares outstanding), −1.2% vs the previous count, 4.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
—
Free cash flow, last 12 months
−$29.4M
This quarter −$7.47M, a year earlier −$5.96M
Net debt
—
Debt —, cash $42M, at Sep 30, 2026
Net income, last 12 months
−$36.2M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 16, 2026.
Revenue and earnings history, 6 fiscal yearsEarnings dates and the stock's moves
Insiders of Unicycive Therapeutics reported 1 open-market purchase and 0 sales since 2022; purchases in 2022.
| Year | Bought | Sold |
|---|---|---|
| 2022 | $12K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Unicycive Therapeutics over the 12 months to Nov 17, 2026: 1 securities case.
0 certified in FY2026 Q3, vs 1 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 5,000 words.
We are a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapies to address significant unmet medical needs, with an initial focus on kidney disease. Founded in 2016, we were established to create a streamlined and efficient drug development platform capable of accelerating the advancement of promising therapies from discovery to commercialization. Currently, our two programs are focused on kidney disease, an area we believe we have the potential to offer medical benefit. Our initial focus is on developing drugs and getting them approved in the U.S., and then to partner with global biopharmaceutical companies in the rest of the world.
And 10 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
A securities lawsuit naming the company as a defendant was filed on Sep 3, 2026 in the U.S. District Court, N.D. California. A filing is an allegation, not a finding.
Patel v. Unicycive Therapeutics, Inc., 3:26-cv-09559A securities lawsuit naming the company as a defendant was filed on Aug 15, 2025 in the U.S. District Court, N.D. California. A filing is an allegation, not a finding.
Elkhodari v. Unicycive Therapeutics, Inc., 3:25-cv-06923Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.
Latest annual report filed Mar 30, 2026, compared with the one filed Mar 31, 2025. Read the filing
All 55 risk factor headings match the year before, give or take wording.
On August 15, 2025, a putative shareholder class action complaint captioned Elkhodari v. Unicycive Therapeutics, Inc., et al., Case No. 3:25-cv-06923-JD (the “Securities Class Action”), was filed in the U.S. District Court for the Northern District of California (“Northern District of California”), naming the Company and certain current officers and/or directors of the Company as defendants.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 48.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (13.1% on ATS, 35.7% with other brokers), above its 26-week average of 46.7%. Weeks of Sep 21 to Oct 16, 2026.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Largest ATS: UBS ATS (12.9%), INTELLIGENT CROSS LLC (12.3%), MS POOL (ATS-4) (9.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Vivo Opportunity Fund Holdings, L.P.
13G · passive · Amended · 3.91M shares · filed Nov 16, 2026
RA Capital Management, L.P.
13G · passive · Amended · 3.09M shares · filed Nov 16, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Since Nov 18, 2025, UNCY is down 43.4% and the index fund is up 4.5%: 48 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much UNCY moves
Beta 1.1 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).